Online citations, reference lists, and bibliographies.
← Back to Search

Isolated Thoracic Perfusion With Chemofiltration For Progressive Malignant Pleural Mesothelioma

K. Aigner, E. Selak, S. Gailhofer
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction Therapy of malignant pleural mesothelioma and especially the adequate role of surgery in this context remain the subject of controversial discussions. Radical surgery in particular, which is associated with substantial morbidity, failed to translate into a definite survival advantage. We report on interim results of an ongoing Phase II study of regional chemotherapy in terms of isolated thoracic perfusion with chemofiltration (ITP-F). Patients and methods Twenty-eight patients (25 male, 3 female, mean age 63.4 years) with advanced pleural mesothelioma were included in this study. Isolation of the chest was achieved by insertion of a venous and arterial stop-flow balloon catheter via a femoral access. The aorta and inferior vena cava were blocked at the level of the diaphragm and the upper arms were blocked by pneumatic cuffs. Chemotherapy, consisting of 60 mg/m2 cisplatin and 15 mg/m2 mitoxantrone, was administered directly into the aorta. The isolated circuit was maintained for 15 minutes followed bŷ45 minutes of chemofiltration with a hemoprocessor until 5 L of filtrate were reached. The endpoints of the study were overall survival and quality of life (QoL). Results Out of 28 patients enrolled in the study, 5 had prior surgeries, 10 patients had systemic chemotherapy, and 5 patients additional irradiation. In all patients in restaging, clinical progress was noted. In all, 162 cycles were administered. Due to chemofiltration, toxicity was within tolerable limits, revealing World Health Organization grade I leucopenia and thrombocytopenia in 9 patients and mucositis grade I in 6 patients. The major surgical complication was inguinal lymphatic fistula in 40% of the cases. Gastrointestinal toxicity and/or neurotoxicity were never observed. One-year survival was 49%, 2-year and 3-year survival was 31%, and 5-year survival was 18%. Median overall survival was 12 months and progression-free survival 9 months. Conclusion ITP-F for patients with advanced pleural mesothelioma, progressive after standard therapies, is an effective and well-tolerated treatment modality, offering comparably long survival data at a good QoL.
This paper references
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1159/000415981
Drug Filtration in High-Dose Regional Chemotherapy
K. Aigner (1988)
Chemotherapy for malignant pleural mesothelioma.
P. Janne (2003)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1136/thx.2007.081430
Population based epidemiology and prognosis of mesothelioma in Leeds, UK
A. Chapman (2008)
10.1038/bjc.2014.312
Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey
G. Ceresoli (2014)
Hypoxic abdominal perfusion for recurrent platin refractory ovarian cancer
K. Aigner (2008)
10.1007/978-3-319-28773-7_33
Toxicity Profiles with Systemic Versus Regional Chemotherapy
Kornelia Aigner (2016)
10.1016/j.soc.2012.12.004
Multimodality treatment of pleural mesothelioma.
David D. Shersher (2013)
10.1016/j.ctrv.2014.10.007
Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
J. Remon (2015)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1002/j.1552-4604.1998.tb04390.x
Pharmacokinetics of Mitomycin C in Pelvic Stopflow Infusion and Hypoxic Pelvic Perfusion with and without Hemofiltration: A Pilot Study of Patients with Recurrent Unresectable Rectal Cancer
S. Guadagni (1998)
Stop-flow in mediastinum and thorax for resistant lymphoma.
S. Guadagni (2000)
10.1007/978-3-642-18173-3_24
Isolated Thoracic Perfusion with Chemofiltration (ITP-F) for Advanced and Pre-treated Non-Small-Cell Lung Cancer
Kornelia Aigner (2011)
10.1016/j.ctrv.2009.09.003
Second-line treatment for malignant pleural mesothelioma.
G. Ceresoli (2010)
10.1016/S0140-6736(14)60795-9
Surgical resection of mesothelioma: an evidence-free practice
Y. Lee (2014)
10.3816/CLC.2003.N.023
Chemotherapy for malignant pleural mesothelioma.
P. Jänne (2003)
Secondline treatment for malignant pleural mesothelioma
GL Ceresoli (2010)
Malignant pleural mesothelioma: factors influencing the prognosis.
T. Mineo (2012)
10.1093/ANNONC/MDM137
Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer.
L. Bijelić (2007)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
10.2471/BLT.13.132118
Asbestos: use, bans and disease burden in Europe
T. Kameda (2014)
10.1097/JTO.0b013e31828353d7
Surgery in mesothelioma--where do we go after MARS?
B. Hiddinga (2013)
10.1148/radiol.12111858
Nonselective transarterial chemoperfusion: a palliative treatment for malignant pleural mesothelioma.
T. Vogl (2013)
[Systemic Treatment of Malignant Pleural Mesothelioma].
T. Nakano (2017)
10.1016/j.lungcan.2014.08.017
Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials.
A. Mansfield (2014)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.1200/JCO.2011.29.15_SUPPL.7006
A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy.
P. Baas (2011)
10.1016/j.jtcvs.2013.01.039
The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass.
V. Rusch (2013)
10.1093/ejcts/ezs418
Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience.
M. Ried (2013)
10.1016/S1470-2045(15)70056-2
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
L. Krug (2015)
10.1016/j.jtcvs.2012.12.037
Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.
D. Sugarbaker (2013)
10.3978/j.issn.2072-1439.2014.05.03
Management of malignant pleural mesothelioma-The European experience.
I. Opitz (2014)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1016/j.ctrv.2012.12.005
Malignant mesothelioma: new insights into a rare disease.
J. Remon (2013)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar